Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p337 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals

Hsieh Evelyn , Fraenkel Liana , Han Yang , Xia Weibo , Insogna Karl , Yin Michael , Zhu Ting , Cheng Xinqi , Li Taisheng

Tenofovir disoproxil fumarate (TDF) is a critical component of first-line antiretroviral regimens for HIV worldwide. However, TDF-containing regimens have been associated with decreased bone mineral density and increased fracture risk, which may in part be mediated through secondary elevations in parathyroid hormone (PTH). Prior cross-sectional data suggest vitamin D binding protein (DBP) levels may increase with TDF exposure leading to a functional vitamin D deficiency, which...

ba0006oc24 | (1) | ICCBH2017

KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH)

Imel Erik , Carpenter Thomas , Gottesman Gary S , Martin Javier San , Mao Meng , Skrinar Alison , Whyte Michael P

Objectives: XLH features renal phosphate (Pi) wasting, hypophosphatemia, rickets, and skeletal deformities from elevated circulating levels of fibroblast growth factor 23 (FGF23). KRN23, an investigational fully human monoclonal antibody, binds FGF23 and inhibits its action. Our Phase 2 study of KRN23 in XLH children (ages 5–12 years) is demonstrating improvements in serum Pi and rickets. Here we present our Phase 2 trial evaluating the efficacy and safety of KRN23 in you...

ba0006p100 | (1) | ICCBH2017

Decreased bone turnover in HIV-infected children on antiretroviral therapy

Shiau Stephanie , Yin Michael , Strehlau Renate , Patel Faeezah , Mbete Ndileka , McMahon Donald , Kuhn Louise , Coovadia Ashraf , Arpadi Stephen

Introduction: Lower bone mineral content (BMC) has been reported in HIV-infected children, as well as those on ritonavir-boosted lopinavir (LPV/r)-based antiretroviral therapy (ART). Older studies of children with HIV report increased bone resorption, but data with current antiretroviral regimens are limited.Methods: This analysis presents data from the CHANGES Bone Study (Johannesburg, South Africa). Whole body (WB) BMC was assessed by dual-energy X-ray...

ba0007p181 | (1) | ICCBH2019

Walking quality of children with healed Perthes disease

Jamil Kamal , Fuller Joel , Li Jamie , Bucknell Michael , McKay Marney , Baldwin Jennifer , Burns Joshua , Munns Craig , Pacey Verity

Objectives: Children with Perthes disease may present with altered walking patterns even at the healed stage of the disease. The aim of the study was to assess the walking endurance, fatiguability and gait changes of children with healed Perthes disease, and to determine if walking endurance is associated with hip function and quality of life.Methods: Fifty-one children (38 males) aged 8–16 years with >3 years post-diagnosis of Perthes disease c...

ba0001pp74 | Bone development/growth and fracture repair | ECTS2013

Metaphyseal fracture healing in a sheep model of low turnover osteoporosis induced by hypothalamic–pituitary disconnection

Bindl Ronny , Oheim Ralf , Pogoda Pia , Beil Frank Timo , Gruchenberg Katharina , Reitmaier Sandra , Wehner Tim , Calcia Enrico , Radermacher Peter , Claes Lutz , Amling Michael , Ignatius Anita

We recently established a large animal model of osteoporosis in sheep using hypothalamic–pituitary disconnection (HPD). As central regulation is important for bone metabolism, HPD-sheep developed severe osteoporosis because of low bone turnover. In this study we investigated metaphyseal fracture healing in HPD-sheep. To elucidate potential pathomechanisms, we included a treatment group receiving thyroxine (T4) and 17β-estradiol. Because clinically osteopor...

ba0001pp162 | Cancer and bone: basic, translational and clinical | ECTS2013

Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer: the ZOTECT Study

Hadji Peyman , Ziller May , Maurer Tobias , Autenrieth Michael , Muth Mathias , Ruebel Amelie , May Christoph , Birkholz Katrin , Diebel Erhardt , Gleissneer Jochen , Rothe Peter , Gschwend Juergen E

Introduction: The prospective, single-arm, open-label ZOTECT study was designed to assess the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients with bone metastases.Methods: Patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) who have not received bisphosphonates for ≥6 months were enrolled at 98 sites in Ge...

ba0001pp474 | Other diseases of bone and mineral metabolism | ECTS2013

Insertion of the clcn7 gene mutation pG213R in mouse induces autosomal dominant osteopetrosis type II

Fattore Andrea Del , Gray Amie K , Ichikawa Shoji , Chu Kang , Mohammad Khalid S , Capannolo Marta , Muraca Maurizio , Teti Anna , Econs Michael J , Alam Imranul

Autosomal dominant osteopetrosis type II (ADO2) is a rare osteosclerotic disease due heterozygous missense mutations of the CLC7 gene encoding the type seven chloride channel. Our two labs independently generated the first C57 black 6 (B6) mouse model of ADO2 by inserting the pG213R-clc7 mutation. Homozygous mice showed lack of tooth eruption and died within 30 days of age with severe osteopetrosis and central nervous system degenera...

ba0002oc8 | Biology | ICCBH2013

Generation of the first mouse model of autosomal dominant type II osteopetrosis harbouring the pG213R-clc7 mutation

Del Fattore Andrea , Gray Amie , Ichikawa Shoji , Chu Kang , Mohammad Khalid S , Capannolo Marta , Capulli Mattia , Muraca Maurizio , Econs Michael J , Teti Anna , Alam Imranul

Autosomal dominant type II osteopetrosis (ADO2) is a rare osteosclerotic disorder due to heterozygous missense mutations of CLC7 gene encoding the type 7 chloride channel. Our two labs (L’Aquila and Indianapolis) independently generated the first C57 black 6 (B6) mouse model of ADO2 by inserting the pG213R-clc7 mutation. We created pG213R-clc7 KI mice using a gene targeting approach. Homozygous mice showed lack of tooth eruption and died within ...

ba0002oc21 | Miscellaneous | ICCBH2013

A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone

Boyce Alison M , Kelly Marilyn H , Brillante Beth A , Kushner Harvey , Wientroub Shlomo , Riminucci Mara , Bianco Paolo , Robey Pamela G , Collins Michael T

Fibrous dysplasia (FD) is a benign skeletal disease caused by activating mutations of Gsα. These mutations lead to formation of abnormal and mechanically unsound bone and fibrotic tissue. Clinical sequelae include deformity, fracture, and pain. Studies in bisphosphonates have shown improvement in bone pain and inconsistent effects on FD mineralization; however interpretation has been limited by a lack of controlled trials.Objecti...